November 2019

Two great papers, recently published in European Urology, confirm that MRI-targeted biopsy is the attractive and reliable diagnostic strategy for prostate cancer compared to the traditional diagnostic pathway of systematic TRUS biopsy:

• an in-depth systematic review and meta-analysis from Veeru Kasivisvanathan et al. summarized only in one image:

• as well as impressive results of a 2-year follow-up of systematic biopsy versus MRI and targeted and systematic biopsy (the randomized ASIST trial) from the Laurence Klotz group, summarized only in one image:

Read more in European Urology:
https://www.europeanurology.com/article/S0302-2838(19)30360-4/fulltext
https://www.europeanurology.com/article/S0302-2838(19)30773-0/fulltext